Evidence map›Paper›PMID 37539086›Full record

ReviewFrontiers in cardiovascular medicine2023

Effect of pretreatment with a P2Y

Yachao Li, Mengjie Lei, Zhigang Zhao, Yanli Yang, Lei An, Jingyao Wang, Xue Sun, Cairong Li, Zengming Xue

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yachao Li *Department of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Mengjie Lei *Department of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Zhigang ZhaoDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Yanli YangDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Lei AnDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Jingyao WangDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Xue SunDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Cairong LiDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Zengming XueDepartment of Cardiology, Langfang People's Hospital, Hebei Medical University, Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang, China.
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to systematically evaluate the effects of different types and doses of pretreatment with P2Y Methods: Electronic databases were searched for studies comparing pretreatment with different types and doses of P2Y Results: A total of 119,014 patients from 21 studies were enrolled, including 13 RCTs and eight observational studies. A total of six types of interventions were included-nonpretreatment (placebo), clopidogrel pretreatment, ticagrelor pretreatment, prasugrel pretreatment, double loading pretreatment (double loading dose of clopidogrel, ticagrelor, prasugrel) and P2Y Conclusions: In patients with NSTE-ACS, pretreatment with P2Y

Indexed as

antiplateletmeta-analysisnon-ST-segment elevation acute coronary syndromeP2Y12 inhibitorpretreatment

Identifiers

PMID37539086
PMCPMC10394276
OpenAlexW4385066837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.